Eli Lilly (LLY) Q1 2026 earnings review
Incretin Engine Roars as Foundayo Approval Opens New Frontier
Lilly delivered a massive beat in Q1 2026, growing revenue by 56% YoY to $19.8 billion and blowing past expectations. The growth is entirely volume-driven (+65%), spearheaded by unstoppable demand for Mounjaro ($8.66B) and Zepbound ($4.16B). However, this incredible volume masked a sharp 13% decline in realized prices, driven by China's NRDL inclusion and U.S. Zepbound dynamics. The biggest news is the FDA approval of Foundayo (orforglipron), an oral GLP-1 without food or water restrictions, effectively neutralizing a primary barrier to primary care adoption. Management confidently raised FY26 revenue guidance by $2 billion to an $83.5 billion midpoint.
🐂 Bull Case
The highly anticipated approval of Foundayo provides Lilly with a scalable, convenient oral option that will drastically expand the total addressable market into primary care and maintenance phases.
While revenue surged 56%, R&D grew only 28% and SG&A grew 19%. This discipline translated top-line hyper-growth into a 156% explosion in Non-GAAP EPS.
🐻 Bear Case
Realized prices dropped 13% in Q1 (compared to 5% in 25Q4 and 10% in 25Q3). This indicates that volume growth is increasingly coming at the expense of unit economics.
The quiet removal of Verzenio from the 'Key Products' metric signals management's recognition that its prior growth engines have permanently plateaued.
⚖️ Verdict: 🟢🟢
Strongly Bullish. Price erosion is a valid concern, but +65% volume growth and the launch of a transformative oral GLP-1 easily overwhelm near-term margin friction. The sheer scale of the incretin cash engine is unmatched.
Key Themes
Foundayo (Orforglipron) Clears FDA
The U.S. FDA officially approved Foundayo for adults with obesity/overweight. Crucially, the label boasts no food and water restrictions, creating a massive competitive moat against existing oral options like semaglutide. This fulfills the launch promise established in 2025 and unlocks the highly scalable small-molecule manufacturing engine to meet global demand.
Volume Surges, but Price Deflation is Accelerating
Lilly's 56% revenue growth was powered entirely by a 65% volume surge, but it masked an accelerating 13% decline in realized prices. The narrative contradicts the prior 'stable pricing' storyline: international prices plummeted 25% due to Mounjaro's inclusion in China's National Reimbursed Drug List (NRDL), while U.S. prices fell 7% on Zepbound/Taltz dynamics. This is a definitive structural headwind.
Aggressive BD Signals Diversification Beyond Incretins
Management is aggressively redeploying incretin cash flows to plug pipeline gaps. Q1 saw agreements to acquire Orna Therapeutics, Centessa, Kelonia, and Ajax. This signals a strategic pivot to secure next-generation tech, specifically in vivo CAR-T cell therapies and sleep-wake disorders, ensuring growth optionality for the 2030s.
Verzenio Quietly Removed from Key Products
In a telling footnote, Lilly noted: 'Effective Q1 2026, Verzenio is excluded from Key Products.' After warning of a U.S. plateau in late 2025, management is formally acknowledging that the breast cancer asset is no longer a growth driver, placing even heavier reliance on the cardiometabolic franchise.
Operating Leverage is Unprecedented
Lilly demonstrated phenomenal cost control. Despite launching major products globally and absorbing a 13% price drop, SG&A grew only 19% ($2.9B) and R&D grew 28% ($3.5B) against 56% revenue growth. This discipline caused Non-GAAP Operating Margin to expand dramatically, powering the 156% YoY EPS growth.
Litigation and Impairment Noise Remains
The company recorded $279 million in asset impairment and restructuring charges primarily related to litigation matters, alongside $584 million in acquired IPR&D. While well-absorbed by current cash flows, consistent one-off legal and BD charges continue to obscure true GAAP profitability.
Other KPIs
Reversing. Down 0.9 percentage points YoY. For the past year, gross margins have steadily expanded (hitting 83.8% for FY25) due to product mix. The reversal this quarter explicitly reflects the heavy -13% toll of lower realized prices globally, proving that manufacturing efficiencies can no longer entirely offset price compression.
Accelerating. Grew an astronomical 81% YoY, driven by a 95% volume spike. Mounjaro's global rollout is hitting critical mass. However, the price paid was steep: a 25% price decline driven largely by the Chinese NRDL.
Guidance
Accelerating absolute dollar expansion but decelerating percentage growth. The $2B guidance raise places the midpoint at $83.5B, representing ~28% YoY growth compared to FY25's $65.2B. This implies that while Q1 grew at 56%, the rest of the year will face significantly tougher base-effect comps.
Accelerating. The midpoint of $36.25 represents an implied ~50% growth rate over FY25's $24.21. This incredible bottom-line flow-through confirms that operating leverage will remain a primary engine for shareholder return, despite gross margin slight compression.
Stable to Accelerating. Raised from 46.0%-47.5%. Management expects SG&A and R&D efficiencies to continue overpowering price declines, structurally rebasing the company's profitability profile.
Key Questions
Foundayo Launch Strategy vs Injectables
With Foundayo now FDA approved without food/water restrictions, what is the precise commercial strategy to avoid cannibalizing Mounjaro and Zepbound? Will this primarily target the cash-pay and maintenance channels?
Pricing Floor
Realized prices dropped 13% globally and 25% internationally due to dynamics like the China NRDL. Where does management see the long-term price-to-volume equilibrium settling for the incretin franchise over the next 12-24 months?
Verzenio Demotion
Verzenio was explicitly removed from the 'Key Products' reporting metric this quarter. Does this confirm that the asset has entered a period of structural revenue decline in the U.S. market?
Cell Therapy Pivot
The acquisitions of Orna and Kelonia Therapeutics point to a massive pivot into in vivo CAR-T and cell therapies. How much of the R&D budget is expected to shift toward oncology and genetic medicines in the back half of the decade?